Amount of qualified patients: CDEC reviewed the uncertainty in the amount of individuals with reasonably severe to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some patients who will be classified as having gentle or average disease could possibly have a significant https://hemgenix16047.bloggerbags.com/41194669/examine-this-report-on-hemgenix